LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the development of precision therapies for genetic heart diseases, today announced the successful completion of a US$19 million Series A financing. LQTT is advancing a series of in-licensed compounds discovered and developed by Sanofi …
Trending at Lumira Ventures
Angelini Pharma and Lumira Ventures launch the Angelini Lumira Biosciences Fund (ALBF)
– Angelini Pharma will invest US$35 million and be the sole investor in this innovative fund – ALBF will invest in early-stage companies developing pharmaceuticals to treat central nervous system disorders and rare diseases – ALBF will complement Lumira’s US$220 …
Lumira Ventures Closes on US$255 Million of New Capital to Build Transformative Healthcare Companies
Oversubscribed Lumira Ventures IV to continue successful focus backing biotechnology and medtech companies in Canada and U.S. Companion strategic fund formed in partnership with international pharmaceutical company During the past 18 months Lumira Ventures completed 8 exit transactions and portfolio …
Lumira Ventures is proud to be the winner of back-to-back VC Regional Impact Award for Western Canada for 2020 and 2021
Lumira Ventures prides itself on being a VC investor that backs promising early-stage health care and life sciences companies with the potential to dramatically improve patient care. It was with this vision that Lumira co-lead a US$61.5M crossover financing round …
Lumira Ventures is pleased to participate in the $92 million Series E financing for BioTheryX
BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving cancer medicines, today announced a $92 million Series E financing led by Farallon Capital Management, with participation from additional new investors Avidity Partners, Deep Track Capital, Janus Henderson Investors, Lumira …
Lumira announces first cohort to join the VIP program
With the establishment of Lumira Ventures Fund IV, the largest life sciences focused venture fund ever raised in Canada, we launched our Lumira Ventures Venture Innovation Program (Lumira VIP). The Lumira VIP is designed for a select and highly qualified …
Lumira portfolio company Antios Therapeutics raises $96 Million in a Series B financing
Antios Therapeutics, Inc. (“Antios”) today announced the successful completion of a $96 million Series B financing. The proceeds from this financing will support the ongoing Phase 2 clinical program which is evaluating the potential for the Company’s lead clinical candidate, …
Lumira completes investment in XyloCor Therapeutics’ Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease
XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing To Advance Novel Gene Therapy Pipeline For Coronary Artery Disease – Company closes additional $22.6 million in new financing – – Proceeds will fund initiation of new clinical trial for lead gene therapy candidate XC001 as …
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings
Series B financing to support ongoing Phase 1/2a clinical trial of Tegavivint in desmoid tumors and initiation of clinical trials in acute myeloid leukemia, non-small cell lung cancer and pediatric cancers HOUSTON, Feb. 16, 2021 /PRNewswire/ — Iterion Therapeutics, Inc. (“Iterion”), …
Lumira portfolio company Notch therapeutics closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies
VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/ — Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. The financing was led …
Fonds de solidarité FTQ Invest US$17.7 Million in Lumira IV Life Sciences Fund
Montréal, February 4, 2021 – As part of its strategy to support Québec’s life sciences sector through well-performing specialized funds, the Fonds de solidarité FTQ (“Fonds”) is investing US$17.7 million (C$22.5 million) in Lumira IV. Over the years, Lumira has …